Gefticip contains Gefitinib, an oral targeted anticancer medicine belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) class. Gefitinib inhibits EGFR signaling, which can contribute to the growth and survival of certain cancer cells.

Gefitinib is primarily used for appropriately selected patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). It is a prescription medicine and should be used under the supervision of a qualified oncologist.

What is Gefitinib?

Gefitinib is a targeted anticancer agent that inhibits the tyrosine kinase activity of EGFR. In tumors driven by activating EGFR mutations, blocking EGFR signaling can interfere with pathways responsible for cancer-cell growth and survival.

Gefitinib is mainly used in the management of locally advanced or metastatic non-small cell lung cancer with appropriate activating EGFR mutations.

Benefits and Uses of Gefticip

Gefticip (Gefitinib) may be prescribed for:

• Treatment of EGFR mutation-positive non-small cell lung cancer
• Management of selected locally advanced or metastatic NSCLC
• Targeted inhibition of abnormal EGFR signaling
• Interference with signaling pathways involved in cancer-cell proliferation
• Targeted treatment based on the molecular characteristics of the tumor

Appropriate molecular testing may be required before treatment to determine whether Gefitinib is suitable.

Dosage Guidelines

The dosage of Gefitinib should be determined by the treating oncologist according to the patient’s diagnosis and clinical condition.

• Gefitinib is commonly administered once daily.
• It can generally be taken with or without food.
• Take Gefticip at approximately the same time each day.
• Follow the prescribed dose and treatment duration carefully.
• Do not change the dose or discontinue treatment without medical advice.
• If swallowing the tablet is difficult, follow the instructions provided by the healthcare professional or product information.

Patients receiving Gefitinib may require monitoring of liver function and assessment for skin, gastrointestinal, and respiratory adverse effects.

Wholesale & Supply

Onco India International can support wholesale and bulk pharmaceutical supply of Gefticip (Gefitinib) for eligible markets and pharmaceutical procurement requirements.

Bulk supply may be suitable for:

• Pharmaceutical distributors
• Hospitals and healthcare institutions
• Oncology distributors
• International pharmaceutical buyers
• Licensed importers and exporters
• Healthcare procurement organizations

Packaging, minimum order quantities, documentation, and availability may vary according to market requirements.

Buying Gefitinib Online

When sourcing Gefticip or other Gefitinib products, buyers should verify the strength, dosage form, manufacturer, batch information, packaging, and applicable quality documentation.

Gefitinib is a prescription anticancer medicine. Pharmaceutical products should be sourced through authorized and appropriately licensed suppliers and used under qualified medical supervision.

Reviews

Individual responses to Gefitinib can vary according to EGFR mutation status, cancer stage, previous treatments, treatment regimen, and individual patient factors.

For pharmaceutical procurement, important considerations include product quality, manufacturing standards, documentation, packaging integrity, and supply reliability.

Quality Assurance

Quality assurance is essential for targeted oncology medicines such as Gefitinib. Products should be manufactured, tested, packaged, and stored according to applicable pharmaceutical quality and regulatory requirements.

Relevant documentation, including available product specifications, certificates, batch information, and package inserts, can be requested where applicable.

Frequently Asked Questions

What is Gefticip used for?

Gefticip contains Gefitinib and is primarily used for selected patients with EGFR mutation-positive non-small cell lung cancer.

What type of medicine is Gefitinib?

Gefitinib is a targeted anticancer medicine classified as an EGFR tyrosine kinase inhibitor (TKI).

How does Gefitinib work?

Gefitinib blocks the tyrosine kinase activity of EGFR, reducing signaling pathways that can promote cancer-cell growth and survival.

Is Gefitinib suitable for all lung cancer patients?

No. Gefitinib is particularly used when appropriate activating EGFR mutations are present. Molecular testing and oncology assessment are important when determining treatment.

How is Gefitinib administered?

Gefitinib is an oral medicine commonly taken once daily, with or without food, according to the prescribed treatment regimen.

What are common side effects of Gefitinib?

Possible adverse effects include diarrhea, acne-like skin rash, dry skin, itching, nausea, and changes in liver-function tests. Serious reactions can also occur.

Can Gefitinib affect liver function?

Yes. Gefitinib may cause elevations in liver enzymes and, less commonly, significant liver injury. Liver-function monitoring may therefore be required.

Can Gefitinib cause lung problems?

Yes. Rarely, Gefitinib can cause interstitial lung disease/pneumonitis, which can be serious. New or worsening cough, shortness of breath, or fever should be promptly reported to a healthcare professional.

Is Gefitinib chemotherapy?

Gefitinib is generally classified as a targeted therapy, specifically an EGFR tyrosine kinase inhibitor, rather than conventional cytotoxic chemotherapy.

Conclusion

Gefticip (Gefitinib) is an oral targeted EGFR tyrosine kinase inhibitor primarily used for selected patients with EGFR mutation-positive non-small cell lung cancer. By inhibiting EGFR signaling, Gefitinib can interfere with pathways involved in tumor-cell growth and survival.

Because Gefitinib requires appropriate patient selection and can cause clinically significant adverse effects, treatment should be guided and monitored by a qualified oncology professional.